InDex Pharmaceuticals: Discontinues development of cobitolimod - Redeye
Redeye provides its comments on yesterday's news that InDex Pharmaceuticals discontinues the development of cobitolimod and will not proceed development of any of its other compounds.
ANNONS
Redeye provides its comments on yesterday's news that InDex Pharmaceuticals discontinues the development of cobitolimod and will not proceed development of any of its other compounds.